This content has been produced by ADG in association with Amgen.

There is still a large gap between guideline-recommended LDL-C target levels in high-risk patients and what is achieved in real world practice, warn leading cardiologists in a new viewpoint article.¹

Led by the president of the European Atherosclerosis Society, Prof Kausik Ray, the authors write that despite “an extensive armamentarium” of LDL cholesterol-lowering therapies for atherosclerotic cardiovascular disease (ASCVD) prevention, implementation remains a challenge.¹

They propose to move away from the concept of high-intensity statin treatment to one of combination therapy that includes statins, ezetimibe and a monoclonal antibody PCSK9 inhibitor as the basic standard of care.¹